Studies Directed at Maximising Achievement of Treatment Free Remission in CML

研究旨在最大限度地实现 CML 的无治疗缓解

• 批准号: nhmrc : GNT1059165
• 负责人: A/Pr Agnes Yong
• 金额: $ 126.84万
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2014
• 资助国家: 澳大利亚
• 起止时间: 2014-01-01 至 无数据
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/studies-directed-maximising-remission-cml/1344681
• 关键词: Studies; Directed; Maximising; Achievement; Treatment

Chronic myeloid leukaemia (CML) can usually be treated effectively with long-term tyrosine kinase inhibitor (TKI) therapy. Remarkably, rare patients who achieve excellent responses can stop treatment altogether without relapsing. Detailed studies of these patients in terms of their genetic background, the biology of their leukaemia and their immune response may help us understand how this is possible, leading to new therapeutic approaches to make treatment-free remission more widely achievable.

慢性粒细胞白血病（CML）通常可以通过长期酪氨酸激酶抑制剂（TKI）治疗得到有效治疗。值得注意的是，极少数获得良好缓解的患者可以完全停止治疗而不会复发。对这些患者的遗传背景、白血病生物学和免疫反应进行详细研究可能有助于我们了解这是如何实现的，从而开发出新的治疗方法，使免治疗缓解更广泛地实现。